Alternate Day Buprenorphine Administration, Phase XI - 16

University of Vermont

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000234

R01DA006969 (U.S. NIH Grant/Contract)

R01-06969-16

NIDA-06969-16

Details and patient eligibility

About

The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.

Sex: All

Ages: 25 to 51 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.